Monday 24 July 2017 'premium' content
Register   |   Forgot password?   |    AusPharmList   |    auspharmjobs.net.au   

Advertisers
and Sponsors

LOGIN  (email address)

PASSWORD

Remember me:
SEARCH SITE:
mail2web.com
CHECK YOUR EMAIL:


No polls are currently active, you can see the results from previous polls here.





To generate a report of the AusPharm Continuing Professional Development activities you have completed for a specified time period (and, if desired, the number of times you have posted to AusPharmList over the same time period), click here. Please note, you need to be logged in to do this.

The Continuing Professional Development activities below will remain active for 12 months from the date of publication. You will be able to do any one of them at any time. ie ALL activities remain 'active' not just the current activity.

While every effort has been made to ensure that material presented is accurate and up to date, new evidence is continually uncovered and what is accurate one week may not stay accurate for long.


AusPharm Continuing Professional Development

RGH Pharmacy E-Bulletin CPD Digest - Issue No 91 :: Chris Alderman : 3/3/2016 : The next in our 2016 series of continuing professional development activities is the RGH E-Bulletin Digest No. 91.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 60-12 → 61-3 (November 23 → December 14, 2015).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Describe the nature of the potential relationship between pholcodine exposure and adverse reactions to neuromuscular blocking agents
  • Discuss the potential role of nicotinamide in the prevention of non-melanoma skin cancer
  • Describe the possible effects of vitamin K derivatives in the maintenance of bone health
  • Discuss the clinical pharmacology of lurasidone.

Accreditation number: A1603AP1.
This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.

Click here to do this Continuing Professional Development activity.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Update on NSAIDs: risks and harms :: Debbie Rigby : 18/2/2016 : The next in our 2016 series of continuing professional development activities is "Update on NSAIDs: risks and harms" by consultant clinical pharmacist Debbie Rigby.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Understand the differences in gastrointestinal and cardiovascular risk between NSAIDs
  • Choose the safest NSAID for patients based on their individual risk factors  and co-morbidities
  • Counsel consumers on the evidence regarding taking NSAIDs with food
  • Appraise the evidence supporting simultaneous administration of paracetamol with ibuprofen.

Accreditation number: A1602AP1.
This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credit) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hours of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.

Click here to do this Continuing Professional Development activity (Premium subscribers).


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 90 :: Chris Alderman : 4/2/2016 : The first in our 2016 series of continuing professional development activities is the RGH E-Bulletin Digest No. 90.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 60-8 → 60-11 (October 26 → November 16, 2015).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Outline the clinical pharmacology of medicinal cannabinoid agents
  • Discuss the treatment of relapsed/refractory multiple myeloma
  • Describe issues to consider when selecting an antidepressant agent for a person with significant cardiovascular disease
  • Discuss the clinical pharmacology of ponatinibIdentify potential candidates for discontinuation from the medication regiment of palliative care patients.

Accreditation number: A1601AP2.
This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.

Click here to do this Continuing Professional Development activity (Premium subscribers).


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 89 :: Chris Alderman : 10/12/2015 : The next in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 89.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 60-4 → 60-7 (September and October 2015).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Identify potential candidates for discontinuation from the medication regiment of palliative care patients
  • Understand the nature of concerns regarding the use of antipsychotics for the management of insomnia
  • Describe the basis for the approval of biosimilar pharmaceutical products for therapeutic use
  • Discuss the risk factors associated with liver injury associated with exposure to flucloxacillin.

Accreditation number: A1601AP1.
This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.

Click here to do this Continuing Professional Development activity. (Premium subscribers)


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 88 :: Chris Alderman : 19/11/2015 : The next in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 88.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 59-12→60-3 (August and September 2015).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Describe risk factors for cardiovascular syndromes associated with NSAID use
  • Understand potential relationships between CCF exacerbation and some
  • treatments for diabetes Discuss the potential relationship between varenicline treatment and neuropsychiatric adverse effects
  • List contraceptive options for women affected by migraine.

Accreditation number: A1512AP1.
This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Age-related Macular degeneration :: Jenny Gowan : 5/11/2015 : The next in our 2015 series of continuing professional development activities is "Age-related macular degeneration" by Dr Jenny Gowan.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Describe the incidence of macular degeneration
  • List risk factors for macular degeneration
  • Describe the differences between dry and wet macular degeneration
  • Assess the role of antioxidant vitamins in the management of dry macular degeneration
  • Discuss the pharmacological treatments available for the management of wet macular degeneration.

Accreditation number: A1511AP1.
This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hour of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.1, 4.2, 7.1, 7.2, 7.3, 8.1.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 87 :: Chris Alderman : 22/10/2015 : The next in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 87.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 59-8→59-11 (August 2015).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Describe clinical features of dysguesia
  • Discuss factors relevant to the use of antidepressants for people with epilepsy
  • Discuss the aetiology and treatment of Complex Regional Pain Syndrome
  • Describe the clinical application of the SAMe-TT2R2 score.

Accreditation number: A1511AP0.
This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 86 :: Chris Alderman : 8/10/2015 : The next in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 86.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 59-4→59-7 (July 2015).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Understand patterns and causes of medication errors that occur in institutional settings
  • Discuss the clinical pharmacology of vortioxetine
  • Describe the basis of allergy to latex used in medical products, including drug products
  • Outline recent advances announced in releases by the US Food and Drug Administration.

Accreditation number: A1510AP1.
This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Hypertension Management – an update :: Angus Thompson : 24/9/2015 : The next in our 2015 series of continuing professional development activities is "Hypertension Management – an update" by Angus Thompson.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Describe the prevalence of hypertension in Australia
  • Recognise when alternatives to in-clinic blood pressure measurement are indicated
  • Describe the blood pressure treatment targets appropriate for different patient groups
  • Outline the approach to initiation and intensification of drug treatment for hypertension.

This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hour of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1510AP0.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.2.2, 4.2.3, 7.1.2, 7.1.3, 7.2.2, 7.2.3.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 85 :: Chris Alderman : 3/9/2015 : The next in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 85.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 58-12→59-3 (June 2015).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Identify common causes of drug-induced hypertension
  • Discuss the clinical pharmacology of lorcanserin and sodium oxybate
  • Discuss the implications of the current literature relating to home BP monitoring and self-titration of antihypertensive treatment.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1509AP1.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 84 :: Chris Alderman : 20/8/2015 : The next in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 84.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 58-8→58-11 (May/June 2015).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Describe issues related to the use of statins after haemorrhagic stroke
  • Discuss the clinical features of neuroleptic malignant syndrome
  • Describe features and management of angioedema associated with ACE Inhibitors
  • Discuss aspects of the clinical pharmacology of thalidomide.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1509AP0.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Insomnia :: Jenny Gowan : 6/8/2015 : The next in our 2015 series of continuing professional development activities is "Insomnia" by Dr Jenny Gowan.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Describe some common sleep disorders
  • Identify some  of the causes of  common sleep disorders
  • Discuss  non-pharmacological treatments  for the management of insomnia
  • Provide advice for good sleep practices 
  • Discuss the  risks and benefits of pharmacological treatments of insomnia.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1508AP1.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 1.3,2.3,4.2,4.3,7.1,7.2,7.3,8.1.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 83 :: Chris Alderman : 23/7/2015 : The next in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 83.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 58-4→58-7 (April/May 2015).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Recognise serious opioid-related toxicities
  • Provide information about the use of denosumab for malignancy-related hypercalcaemia
  • Outline the clinical pharmacology of alemtuzumab and suvorexant.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1508AP0.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Shingles :: Ella van Tienen : 2/7/2015 : The next in our 2015 series of continuing professional development activities is “Shingles” by part-time private hospital pharmacist, a consultant pharmacist performing medication reviews in residential facilities and HMRs, etc. Dr Ella Van Tienen.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Provide appropriate information, resources and referral to consumers seeking advice on presentations of unilateral rash, or shingles-specific requests
  • Describe the common and serious complications of shingles infections
  • Discuss the benefits of antiviral therapy and the herpes zoster vaccine.

This activity has been accredited for 0.75 hour of Group 1 CPD (or 0.75 CPD credits) suitable for inclusion in an individual pharmacist's CPD plan which can be converted to 0.75 hour of Group 2 CPD (or 1.5 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1507AP1.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4,1, 6.1, 6.3.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 82 :: Chris Alderman : 18/6/2015 : The next in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 82.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 57-12→58-3 (March/April 2015).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Describe the latest views about treatment of male-gender urinary tract infections
  • Discuss the treatment of vitamin B12 deficiency
  • Outline issues in contraceptive selection for women with known risk factors
  • Demonstrate understanding of issues relating to the use of dosage administration aids (DAAs).

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1507AP0.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










New medicines for COPD :: Debbie Rigby : 4/6/2015 : The next in our 2015 series of continuing professional development activities is "New medicines for COPD" by consultant clinical pharmacist Debbie Rigby.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Assess place in therapy for new medicines for the treatment of COPD
  • Appraise differences and benefits of new devices
  • Choose most appropriate device for a patient.

This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hour of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1506AP1.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 6.1, 6.2, 7.1, 7.2.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 81 :: Chris Alderman : 21/5/2015 : The next in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 81.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 57-8→57-11 (February/March 2015).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Discuss the clinical pharmacology of patiromer and aclidinium
  • Outline the key findings of the CitAD trial
  • Describe new insights relating to the optimal duration of dual antiplatelet therapy after placement of coronary stents.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1506AP0.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 80 :: Chris Alderman : 7/5/2015 : The next in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 80.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 57-4→57-7 (January/February 2015).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Describe drug treatments that have been used as a means to prevent non-melanoma skin cancer
  • Outline new knowledge relating to the treatment of Clostridium Difficile infection
  • Discuss various electrolyte abnormalities that may relate to drug therapy.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1505AP1.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Gout and Hyperuricaemia :: Angus Thompson : 23/4/2015 : The next in our 2015 series of continuing professional development activities is "Gout and Hyperuricaemia" by Angus Thompson.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Describe the factors that lead to the development of gout and hyperuricaemia
  • Recognise the need for holistic management of patients with gout and hyperuricaemia
  • Help optimise the management of patients with acute gout and chronic hyperuricaemia.

This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hour of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1505AP0.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.2.2, 4.2.3, 7.1.2, 7.1.3, 7.2.2, 7.2.3.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 79 :: Chris Alderman : 9/4/2015 : The next in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 79.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 56-11→57-2 (November/December 2014).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Outline novel drug treatment options that have been assessed for the management of resistant schizophrenia
  • Discuss the clinical features of anaphylaxis
  • Discuss the clinical pharmacology or praculopride
  • Discuss the potential clinical applications of neprilysin inhibitors.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1504AP0.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










What are the side effects? :: Jenny Gowan : 26/3/2015 : The next in our 2015 series of continuing professional development activities is "What are the side effects?" by Dr Jenny Gowan.

Learning objectives

After completing this activity, pharmacists should be able to:

  • discuss with patients relevant side effects of medications, what to watch for and methods to minimise where possible
  • discuss the differences between side effects and adverse drug reactions and what action to take
  • optimise adherence
  • recognise differences in  health literacy  
  • recognise the impact of the placebo and nocebo effects
  • avoid risk of litigation by warning of known risks.

This activity has been accredited for 1.5 hour of Group 1 CPD (or 1.5 CPcredits) suitable for inclusion in an individual pharmacist's CPD plan which can be converted to 1.5 hour of Group 2 CPD (or 3 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1503AP1.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 1.3, 2.1, 2.2, 2.3, 4.1, 4.2, 7.1, 7.2, 7.3, 8.1.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 78 :: Chris Alderman : 12/3/2015 : The next in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 78.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 56-7→56-10 (October/November 2014).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Describe aspects of the recently updated Australian Asthma Handbook
  • Discuss the clinical pharmacology of tolvaptan
  • List some of the medications than can cause neuropathy

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1503AP0.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Depression, delirium or dementia in the elderly – what are we looking at? :: Ella van Tienen : 19/2/2015 : The next in our 2015 series of continuing professional development activities is “Depression, delirium or dementia in the elderly – what are we looking at?” by consultant pharmacist, uni lecturer, etc. Dr Ella Van Tienen.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Discuss between the common features of depression, delirium and dementia
  • Demonstrate an understanding of the screening tools used in the assessment of altered cognition in the elderly
  • Discuss the appropriate treatment options for presentations of altered cognitive states.

This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hour of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1501AP0.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.2.1, 4.2.2, 4.2.3, 7.1.1, 7.1.2, 7.1.3, 7.2.2, 7.2.3.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 77 :: Chris Alderman : 5/2/2015 : The first in our 2015 series of continuing professional development activities is the RGH E-Bulletin Digest No. 77.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 56-3→56-6 (September/October 2014).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Understand the potential causative contribution of medications to the development of urinary retention
  • List important adverse effects of the cholinesterase inhibitors
  • Discuss the clinical pharmacology of anidulafungin and mirabegron.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1502AP0.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 76 :: Chris Alderman : 11/12/2014 : The next in our 2014 series of continuing professional development activities is the RGH E-Bulletin Digest No. 76.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 55-11→56-2 (September 2014).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Describe key principles from the 2014 update of the Australian Asthma Handbook
  • Discuss the important issues to consider in reporting of adverse drug reactions
  • Outline findings in relation to the effects of aspirin in reducing cancer risk
  • Discuss the clinical pharmacology of dipeptidyl peptidase inhibitors.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1412AP0.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Allergic rhinitis :: Debbie Rigby : 27/11/2014 : The next in our 2014 series of continuing professional development activities is "Allergic rhinitis" by consultant clinical pharmacist Debbie Rigby.

Learning objectives

After completing this activity, pharmacists should be able to:

  • List the range of therapies available to treat allergic rhinitis
  • Select appropriate treatment based on type, frequency and severity of symptoms
  • Advise patients on management of allergic rhinitis.

This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hour of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1408AP0.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 6.1, 6.2, 7.1, 7.2.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 75 :: Chris Alderman : 13/11/2014 : The next in our 2014 series of continuing professional development activities is the RGH E-Bulletin Digest No. 75.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 55-7→10 (August 2014).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Discuss the principles of treatment of psoriatic arthritis with apremilast
  • Outline key aspects of the "Choosing Wisely®" geriatrics guidance
  • Describe the clinical pharmacology of midodrine.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1411AP0.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Reducing risk of diabetes complications :: Jenny Gowan : 30/10/2014 : The next in our 2014 series of continuing professional development activities is "Reducing risk of diabetes complications" by Dr Jenny Gowan.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Determine key considerations that may need to be taken into account for team care when assisting a person with diabetes manage their medications
  • Identify including lifestyle changes which can reduce the risk of complications
  • Educate patients on the need to optimise cardiovascular, skin, eye, foot care risk factors which impact on diabetes management
  • Reinforce the need for regular monitoring of cardiovascular as well as hypoglycaemic adherence.

This activity has been accredited for 1.5 hour of Group 1 CPD (or 1.5 CPcredits) suitable for inclusion in an individual pharmacist's CPD plan which can be converted to 1.5 hour of Group 2 CPD (or 3 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1411AP0.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 1.3, 2.1, 2.2, 2.3, 4.1, 4.2, 7.1, 7.2, 7.3.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 74 :: Chris Alderman : 16/10/2014 : The next in our 2014 series of continuing professional development activities is the RGH E-Bulletin Digest No. 74.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 55-2, 3, 5 & 6 (June/July 2014).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Explain the concept of prescribing cascades
  • Discuss the role of aspirin for stroke prevention in atrial fibrillation
  • Outline the use of iloprost for Raynaud's phenomenon
  • Describe options for the treatment of depression during pregnancy.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1410AP0.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Anticoagulation in atrial fibrillation :: Dr Luke Bereznicki : 2/10/2014 : The next in our 2014 series of continuing professional development activities is "Anticoagulation in atrial fibrillation" by Associate Professor Luke Bereznicki.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Compare the effectiveness and safety of novel anticoagulants;
  • Apply stroke and bleeding risk scores; and
  • Discuss the advantages and disadvantages of the available oral anticoagulant medications.

This activity has been accredited for 1.5 hour of Group 1 CPD (or 1.5 CPcredits) suitable for inclusion in an individual pharmacist's CPD plan which can be converted to 1.5 hour of Group 2 CPD (or 3 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1409AP1.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 6.1, 6.2, 7.1, 7.2.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 73 :: Chris Alderman : 18/9/2014 : The next in our 2014 series of continuing professional development activities is the RGH E-Bulletin Digest No. 73.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 54-9→55-1 (May/June 2014).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Discuss the nature and treatment of myelofibrosis
  • Discuss the use of Garcinia cambogia as a complementary medicine
  • Specify the medications that can be used in the management of high output GI stoma
  • Describe the nature and treatment of akathisia.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1409AP0.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










New Australian asthma guidelines :: Debbie Rigby : 28/8/2014 : The next in our 2014 series of continuing professional development activities is "New Australian asthma guidelines" by Debbie Rigby.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Identify changes in the new edition of the Australian Asthma Handbook
  • Assess control of asthma in adults and children
  • Discuss when asthma medication should be stepped up or down
  • Advise patients with asthma on lifestyle interventions and complementary therapies.

This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hour of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1408AP0.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 6.1, 6.2, 7.1, 7.2.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 72 :: Chris Alderman : 14/8/2014 : The next in our 2014 series of continuing professional development activities is the RGH E-Bulletin Digest No. 72.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 54-5→54-8 (April/May 2014).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Describe the nature and prevalence of drug-related QT interval prolongation
  • Discuss the clinical pharmacology of infliximab and glycopyrronium
  • Discuss the place of drug therapy in the management of venous thromboembolism.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1408AP1.

Click here to do this Continuing Professional Development activity. 


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










The Challenge of Antimicrobial Resistance :: Angus Thompson : 31/7/2014 : The next in our 2014 series of continuing professional development activities is "The Challenge of Antimicrobial Resistance" by Angus Thompson.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Describe the factors that have made tackling antimicrobial resistance an international priority
  • Outline strategies that may be useful in addressing the challenge of antimicrobial resistance
  • Recognise opportunities in pharmacy practice that may assist with the prudent use of antimicrobials.

This activity has been accredited for 1.5 hour of Group 1 CPD (or 1.5 CPcredits) suitable for inclusion in an individual pharmacist's CPD plan which can be converted to 1.5 hour of Group 2 CPD (or 3 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1407AP1.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.2.2, 4.2.3, 7.1.2, 7.1.3, 7.2.2, 7.2.3.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 71 :: Chris Alderman : 17/7/2014 : The next in our 2014 series of continuing professional development activities is the RGH E-Bulletin Digest No. 71.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 54-1→54-4 (March/April 2014).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Discuss the various elements of the recently produced evidence-based Cancer Council Australia clinical practice guidelines for the management of cancer pain in adults
  • Identify causes of drug-induced and other forms of parotitis
  • Outline the clinical pharmacology of pimavanserin and droxidopa.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1407AP0.

Click here to do this Continuing Professional Development activity.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Analgesics for low back pain and the pharmacists’ role :: Jenny Gowan : 3/7/2014 : The next in our 2014 series of continuing professional development activities is "Analgesics for low back pain and the pharmacists’ role" by Dr Jenny Gowan.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Describe the pharmacological treatments available for the management of low back pain
  • Identify serious cases of acute back pain and refer to general practitioner when necessary
  • Screen patients for possibility of adverse events of common analgesics
  • Discuss the resources available to support pharmacists in pain management
  • Reinforce key messages used by general practitioners and allied health workers in pain management.

This activity has been accredited for 1.5 hour of Group 1 CPD (or 1.5 CPcredits) suitable for inclusion in an individual pharmacist's CPD plan which can be converted to 1.5 hour of Group 2 CPD (or 3 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1405AP0.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 1.3, 2.1, 2.2, 2.3, 4.1, 4.2, 7.1, 7.2, 7.3, 8.1.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 70 :: Chris Alderman : 19/6/2014 : The next in our 2014 series of continuing professional development activities is the RGH E-Bulletin Digest No. 70.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 53-8; 53-10→12 (February/March 2014).

You can access these E-Bulletins individually here

After completing this activity, pharmacists should be able to:

  • Describe features associated with Charles Bonnet syndrome
  • Outline recent research findings relating to the safety of testosterone supplementation
  • Understand the basis for drug interactions mediated by P-glycoprotein
  • Discuss adverse effects associated to ticagrelor.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1406AP0.

Click here to do this Continuing Professional Development activity.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Travel medicine :: Ella van Tienen : 5/6/2014 : The next in our 2014 series of continuing professional development activities been put together for us by Ella Van Tienen.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Discuss the common infections encountered by travellers and the role of pharmaceuticals in their prevention and treatment
  • Recognise the range of conditions that travellers may encounter and be able to advise on self-treatment strategies
  • Provide appropriate information, resources and referral to consumers seeking travel medicine advice.

This activity has been accredited for 1.5 hour of Group 1 CPD (or 1.5 CPcredits) suitable for inclusion in an individual pharmacist's CPD plan which can be converted to 1.5 hour of Group 2 CPD (or 3 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1405AP1.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 6.1.1, 6.1.2, 6.1.3, 6.2.1, 6.2.2, 6.2.3, 6.3.1.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 69 :: Chris Alderman : 22/5/2014 : The next in our 2014 series of continuing professional development activities is the RGH E-Bulletin Digest No. 69.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 53-3 → 53-7 (January/February 2014).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Describe the various geriatric syndromes caused by medicines
  • Discuss aspects of the relationship between hypomagnesaemia and treatment with PPIs
  • List safety concerns related to the use of Electronic Cigarettes
  • Outline principles that should be considered during antidepressant changeoverIdentify the clinical features of heterotrophic ossification and have insight into the management of the condition.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1405AP2.

Click here to do this Continuing Professional Development activity.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Peripheral Arterial Disease :: Angus Thompson : 1/5/2014 : The next in our 2014 series of continuing professional development activities is "Peripheral Arterial Disease (PAD)" by Angus Thompson.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Describe the risk factors and epidemiology of Peripheral Arterial Disease
  • Identify patients presenting in the pharmacy with symptoms suggestive of Peripheral Arterial Disease
  • Recognise opportunities to optimise management of Cardiovascular Disease risk factors in Peripheral Arterial Disease.

This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hour of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1404AP1.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 4.2.2, 4.2.3, 7.1.2, 7.1.3, 7.2.2, 7.2.3.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










Probiotics :: Debbie Rigby : 3/4/2014 : The next in our 2014 series of continuing professional development activities is "Probiotics" by Debbie Rigby.

Learning objectives

After completing this activity, pharmacists should be able to:

  • List the conditions for which good evidence of efficacy for probiotics exists
  • Detail the strains of probiotics most efficacious for various conditions
  • Counsel consumers on the efficacy and benefits of probiotics
  • Construct a therapeutic trial with consumers.

This activity has been accredited for 1 hour of Group 1 CPD (or 1 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 1 hour of Group 2 CPD (or 2 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1404AP0.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 6.2.2, 6.3.1, 6.3.2.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.










RGH Pharmacy E-Bulletin CPD Digest - Issue No 68 :: Chris Alderman : 20/3/2014 : The next in our 2014 series of continuing professional development activities is the RGH E-Bulletin Digest No. 68.

This CPD activity assesses your understanding of four recent RGH Pharmacy E-Bulletins, Volumes 52-11 → 53-3 (December 2013/January 2014).

You can access these E-Bulletins individually here or as a group here (this Digest includes the 4 bulletins, the references and the questions).

After completing this activity, pharmacists should be able to:

  • Discuss trial outcomes in relation to the treatment of comorbid diabetes and CCF
  • Describe the clinical pharmacology of abiraterone
  • Describe important ocular side effects associated with psychotropic drugs
  • Discuss the potential role of romosozumab as a treatment for osteoporosis.

This activity has been accredited for 0.5 hours of Group 1 CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group 2 CPD (or 1 CPD credit) upon successful completion of relevant assessment activities.
Accreditation number: A1403AP1.

Click here to do this Continuing Professional Development activity.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CPD program, MIMS.


Click here to do this Continuing Professional Development activity.










Dysphagia and crushing medications :: Jenny Gowan : 6/3/2014 : The next in our 2014 series of continuing professional development activities is "Irritable Bowel Syndrome" by Dr Jenny Gowan.

Learning objectives

After completing this activity, pharmacists should be able to:

  • Determine  if a person can  swallow prescribed medications
  • Provide strategies  to assist swallowing
  • Research accurate information to assist  decision making  as to safety to crush or not
  • Identify those products which should not be crushed or chewed  
  • Suggest alternative dose forms or products  to prescribers, nursing staff  and patients  where appropriate.

This activity has been accredited for 1.5 hour of Group 1 CPD (or 1.5 CPcredits) suitable for inclusion in an individual pharmacist's CPD plan which can be converted to 1.5 hour of Group 2 CPD (or 3 CPD credits) upon successful completion of relevant assessment activities.
Accreditation number: A1403AP0.

The 2010 Competency Standards addressed by this activity include (but may not be limited to): 1.3, 2.1, 2.2, 2.3, 4.1, 4.2, 7.1, 7.2, 7.3.


AusPharm gratefully acknowledges the financial support provided by the sponsors of our CE program, MIMS.


Click here to do this Continuing Professional Development activity.











About this page 

These activities will take approximately 30 minutes to complete and has been formally recognised by the Pharmaceutical Society of Australia (Recognition No: CR08-0012 : 1 CPD&PI point), The Australian Association of Consultant Pharmacy and The Australian College of Pharmacy Practice and Management. To add your PSA, AACP or ACPPM member number to our database (so you can receive credit for completing this activity) click here.


Ready to advance your practice?

Powerful Productive Tracking

Guildcare - one Seamless Software Solution

MIMS

Complement your pharmacy career

Don't rush to crusg - a PBA required text

Australian Medicines Handbook

easyBLIST, pack smarter, pack quicker

Fred Dispense

What's NXT?

Pharmaceutical Defence Limited

PCCA

eRx paperless - do you claiming in the cl0ud

Australian College of Pharmacy

Fred Health

MIMS

APF23 - Australia’s everyday guide to pharmacy practice

Pharmacy Pro

Click here to advertise here

JR Pharmacy Services